The role of systemic therapies in the management of melanoma brain metastases

Current Opinion in Oncology

Volumn 26, Issue 2, 2014, Pages 222-229

  Lyle, Megan ^a   Long, Georgina V ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

BRAF inhibitors; Brain metastases; Ipilimumab; Malignant melanoma; Programmed death 1 antibody

Indexed keywords

ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; HUMANS; IMMUNOTHERAPY; MELANOMA; MOLECULAR TARGETED THERAPY; PROTO-ONCOGENE PROTEINS B-RAF; TREATMENT OUTCOME;

EID: 84894036834     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000057     Document Type: Review

References (53)

1. Amer MH, Al-Sarraf M, Baker LH, et al. Malignant melanoma and central nervous system metastases: Incidence, diagnosis, treatment and survival. Cancer 1978; 42:660-668
2. Davies MA, Liu P, McIntyre S, et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer 2010; 117:1687-1696
3. Sampson JH, Carter JH, Friedman AH, Siegler HF. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 1998; 88:11-20
4. Staudt M, Lasithiotakis K, Leiter U, et al. Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer 2010; 102:1213-1218
5. Fife KM, Colman MH, Stevens GN, et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 2004; 22: 1293-1300
6. Miller D, Zappala V, Hindy El N, et al. Intracerebral metastases of malignant melanoma and their recurrences: A clinical analysis. Clin Neurol Neurosurg 2013; 115:1721-1728
7. Agarwala SS, Kirkwood JM, Gore M, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: A phase II study. J Clin Oncol 2004; 22:2101-2107
8. Avril MF, Aamdal S, Grob JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: A phase III study. J Clin Oncol 2004; 22:1118-1125
9. Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: An open-label, phase 2 trial. Lancet Oncol 2012; 13:459-465
10. Di Giacomo AM, Ascierto PA, Pilla L, et al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): An open-label, single-Arm phase 2 trial. Lancet Oncol 2012; 13:879-886
11. Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): A multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13:1087-1095
12. Dummer R, Goldinger S, Turtschi C, et al. Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study. Eur J Cancer (in press)
13. Kefford R, Malo M, Arance A, et al. Vemurafenib in metastatic melanoma patients with brain metastases: An open-label, single-Arm, phase 2, multicenter study. Philadelphia, USA: Society for Melanoma Research Congress; 2013
14. Chen G, Davies MA. Emerging insights into the molecular biology of brain metastases. Biochem Pharmacol 2012; 83:305-314
15. Yano S, Shinohara H, Herbst RS, Kuniyasu H. Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Res 2000; 60:4959-4967
16. Küsters B, Leenders WP, Wesseling P, et al. Vascular endothelial growth factor-A165 induces progression of melanoma brain metastases without induction of sprouting angiogenesis. Cancer Res 2002; 62:341-345
17. Xie TX, Huang FJ, Aldape KE, et al. Activation of Stat3 in human melanoma promotes brain metastasis. Cancer Res 2006; 66:3188-3196
18. Marchetti D, Li J, Shen R. Astrocytes contribute to the brain-metastatic specificity of melanoma cells by producing heparanase. Cancer Res 2000; 60:4767-4770
19. Murry BP, Blust BE, Singh A, et al. Heparanase mechanisms of melanoma metastasis to the brain: Development and use of a brain slice model. J Cell Biochem 2006; 97:217-225
20. Davies MA, Stemke-Hale K, Lin E, et al. Integrated molecular and clinical analysis of AKT activation in metastatic melanoma. Clin Cancer Res 2009; 15:7538-7546
21. Niessner H, Forschner A, Klumpp B, et al. Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases. Cancer Med 2013; 2:76-85
22. Bucheit AD, Joseph RW, Milton D, et al. PTEN loss correlates with shorter time to brain metastasis and overall survival in stage IIIB/C melanoma patients. Amsterdam, Netherlands: The European Cancer Congress; 2013
23. Hamilton R, Krauze M, Romkes M, et al. Pathologic and gene expression features of metastatic melanomas to the brain. Cancer 2013; 119:2737-2746
24. Mittapalli RK, Vaidhyanathan S, Dudek AZ, Elmquist WF.Mechanisms limiting distribution of the threonine-protein kinase B-RaFV600E inhibitor dabrafenib to the brain: Implications for the treatment of melanoma brain metastases. J Pharmacol and Exp Ther 2013; 344:655-664
25. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17:2105-2116
26. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: Long-Term survival update. Cancer J Sci Am 2000; 6 (Suppl 1):S11-S14
27. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. J Am Med Assoc 1994; 271:907-913
28. Guirguis LM, Yang JC, White DE, et al. Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases. J Immunother 2002; 25:82-87
29. Chu MB, Fesler MJ, Armbrecht ES, et al. High-dose interleukin-2 (HD IL-2) therapy should be considered for treatment of patients with melanoma brain metastases. Chemother Res Pract 2013; 29:1-7
30. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723
31. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-2526
32. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res 2009; 15:7412-7420
33. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369:134-144
34. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454
35. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369:122-133
36. Hamid O, Sosman JA, Lawrence DP, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PDL-1 antibody in patients with locally advanced or metastatic melanoma (mM). ASCO Meeting Abstracts 2013; 31 (15-suppl); 9010
37. Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver mutations in melanoma. Cell 2012; 150:251-263
38. Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011; 29:1239-1246
39. Menzies AM, Haydu LE, Visintin L, et al. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res 2012; 18:3242-3249
40. Jakob JA, Bassett RL Jr, Ng CS, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2011; 118: 4014-4023
41. Lyle M, Long GV. Diagnosis and treatment of KIT-mutant metastatic melanoma. J Clin Oncol 2013; 31:3176-3181
42. Ascierto PA, Schadendorf D, Berking C, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: A nonrandomised, open-label phase 2 study. Lancet Oncol 2013; 14: 249-256
43. Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: A phase 1 dose-escalation trial. Lancet 2012; 379:1893-1901
44. Raizer JJ, Hwu WJ, Panageas KS, et al. Brain and leptomeningeal metastases from cutaneous melanoma: Survival outcomes based on clinical features. Neuro-Oncology 2008; 10:199-207
45. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-2516
46. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366:707-714
47. Narayana A, Mathew M, Tam M, et al. Vemurafenib and radiation therapy in melanoma brain metastases. J Neurooncol 2013; 113:411-416
48. Boussemart L, Boivin C, Claveau J, et al. Vemurafenib and radiosensitization. J Am Med Assoc Dermatol 2013; 149:855-857
49. Anker CJ, Ribas A, Grossmann AH, et al. Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma. J Clin Oncol 2013; 31:e283-e287
50. Klein O, Clements A, Menzies AM, et al. BRAF inhibitor activity in V600R metastatic melanoma. Eur J Cancer 2013; 49:1073-1079
51. Klein O, Clements A, Menzies AM, et al. BRAF inhibitor activity in V600R metastatic melanoma: Response. Eur J Cancer 2013; 49:1797-1798
52. Mittapalli RK, Vaidhyanathan S, Sane R, Elmquist WF. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: Vemurafenib (PLX4032). J Pharmacol and Exp Ther 2012; 342:33-40
53. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367:1694-1703